Expert in targeted protein degradation and drug discovery will support development of the Company’s portfolio of novel small molecule degraders

Cambridge, UK, 28 July 2025: PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the appointment of Dr Adam Gilbert to its Scientific Advisory Board. In the role, Adam will support PhoreMost to advance its portfolio of novel small molecule degraders and molecular glues arising from its GlueSEEKER^® platform.

Most recently an Executive Director and External Accelerator Lead at Pfizer, Adam brings over 30 years of experience in biopharma, drug discovery, and business development. In his numerous roles at Pfizer, Adam led the Design and Synthesis Sciences platform medicinal chemistry group to successfully deliver targeted covalent inhibitors, protein homeostasis modulators, and vaccine antigens. He is co-inventor of LITFULO™ (Ritlecitinib), a covalent JAK3/TEC inhibitor that was recently approved to treat Alopecia Areata, and his group helped deliver ABRYSVO™ (RSVPreF), a preventative Respiratory Syncytial Virus vaccine and COMIRNATY^® (BNT162b2) the Pfizer-BioNTech mRNA COVID-19 vaccine. Adam holds a Ph.D in organic chemistry from Columbia University.

Dr Christian Dillon, CSO, PhoreMost, said: “Adam’s extensive experience and expertise in drug discovery, especially as a KOL in the targeted protein degradation field, will be invaluable in advancing our pipeline of novel degraders in both oncology and inflammation. His proven track record in delivering new therapeutics to market will be pivotal as we progress into clinical stages. As a company, we have focused on building a team with world-class scientific and commercial expertise, welcoming Adam to our Scientific Advisory Board is a key part of that and we are honoured to have his support as we cement our position as leaders in degrader-based drug discovery.”

Dr Adam Gilbert, SAB Member, PhoreMost, commented: “Molecular glues are a very promising therapeutic modality, which hold huge potential to address undruggable targets. Having been an active part of the development of this field, I am very excited by the possibilities of PhoreMost’s platforms. I’ve joined the team at a particularly interesting stage given the recent validation of  GlueSEEKER, and look forward to working with the team to translate identified novel molecular glues into commercially viable assets, addressing key challenges associated with other degrader therapeutics and unlocking the next generation of medicines.”

Expert in targeted protein degradation and drug discovery will support development of the Company’s portfolio of novel small molecule degraders

Cambridge, UK, 28 July 2025: PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the appointment of Dr Adam Gilbert to its Scientific Advisory Board. In the role, Adam will support PhoreMost to advance its portfolio of novel small molecule degraders and molecular glues arising from its GlueSEEKER® platform.

Most recently an Executive Director and External Accelerator Lead at Pfizer, Adam brings over 30 years of experience in biopharma, drug discovery, and business development. In his numerous roles at Pfizer, Adam led the Design and Synthesis Sciences platform medicinal chemistry group to successfully deliver targeted covalent inhibitors, protein homeostasis modulators, and vaccine antigens. He is co-inventor of LITFULO™ (Ritlecitinib), a covalent JAK3/TEC inhibitor that was recently approved to treat Alopecia Areata, and his group helped deliver ABRYSVO™ (RSVPreF), a preventative Respiratory Syncytial Virus vaccine and COMIRNATY® (BNT162b2) the Pfizer-BioNTech mRNA COVID-19 vaccine. Adam holds a Ph.D in organic chemistry from Columbia University.

Dr Christian Dillon, CSO, PhoreMost, said: “Adam’s extensive experience and expertise in drug discovery, especially as a KOL in the targeted protein degradation field, will be invaluable in advancing our pipeline of novel degraders in both oncology and inflammation. His proven track record in delivering new therapeutics to market will be pivotal as we progress into clinical stages. As a company, we have focused on building a team with world-class scientific and commercial expertise, welcoming Adam to our Scientific Advisory Board is a key part of that and we are honoured to have his support as we cement our position as leaders in degrader-based drug discovery.”

Dr Adam Gilbert, SAB Member, PhoreMost, commented: “Molecular glues are a very promising therapeutic modality, which hold huge potential to address undruggable targets. Having been an active part of the development of this field, I am very excited by the possibilities of PhoreMost’s platforms. I’ve joined the team at a particularly interesting stage given the recent validation of  GlueSEEKER, and look forward to working with the team to translate identified novel molecular glues into commercially viable assets, addressing key challenges associated with other degrader therapeutics and unlocking the next generation of medicines.”

About PhoreMost Ltd www.phoremost.com 

PhoreMost is a next-generation targeted protein degradation (TPD) company developing a pipeline of first-in-class and best-in-class degrader therapeutics within oncology and inflammation.

TPD is a promising new way to eliminate toxic or disease-associated targets from cells, with degradation-based therapies now becoming an integral approach to tackling undruggable targets. However, despite there being over 600 known E3 ligases, the pharma industry is currently reliant upon a very small number, such as Cereblon, for degrader-based drug development.

PhoreMost is unlocking the full potential of TPD and has pioneered the use of mini-protein based engineering via its proprietary platforms, SITESEEKER® and GlueSEEKER®, towards developing novel therapeutic approaches to TPD. 
The Company has progressed multiple next-generation ligase programmes through proof-of-concept and is advancing multiple degrader assets towards preclinical studies. PhoreMost also has a number of disclosed alliances with partners, including Roche, Boehringer Ingelheim and Sentinel Oncology.

Follow PhoreMost on LinkedIn @PhoreMost and X @PhoreMostLtd.